Literature DB >> 2150671

Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.

B A Conley1, M J Egorin, V Sinibaldi, D A Van Echo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2150671     DOI： 10.1007/bf00198592

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  The disposition of the new anthracycline antibiotic, menogarol, in mice.

Authors:  P Dodion; B K Chang; M J Egorin; E A Olman; K L Engisch; N R Bachur
Journal:  Drug Metab Dispos       Date:  1984 May-Jun       Impact factor: 3.922

2.  Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

Authors:  M J Egorin; D A Van Echo; M Y Whitacre; A Forrest; L M Sigman; K L Engisch; J Aisner
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

3.  Metabolism and disposition of menogaril (NSC 269148) in the rabbit.

Authors:  P Dodion; M J Egorin; K L Engisch; N R Bachur
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

4.  Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.

Authors:  M J Egorin; B A Conley; A Forrest; E G Zuhowski; V Sinibaldi; D A Van Echo
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

5.  Phase II study of intravenous menogaril in patients with advanced breast cancer.

Authors:  C Sessa; S Gundersen; W ten Bokkel Huinink; J Renard; F Cavalli
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

6.  Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.

Authors:  L M Sigman; D A Van Echo; M J Egorin; M Y Whitacre; J Aisner
Journal:  Cancer Treat Rep       Date:  1986-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.